Deal snapshot: Amgen to Acquire Tavneos Maker ChemoCentryx for USD 52/Share.

MANews-(C)2009-2022

US-based biotechnology company Amgen (NASDAQ: AMGN) has entered into a definitive agreement under which it will acquire biopharmaceutical company ChemoCentryx, Inc., (NASDAQ: CCXI) for USD 52 per share in cash, representing an enterprise value of approximately USD 3.7bn, the company said.

ChemoCentryx is focused on orally administered...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT